EZH2 promotes proliferation and invasiveness of prostate cancer cells

被引:114
作者
Bryant, R. J.
Cross, N. A.
Eaton, C. L.
Hamdy, F. C.
Cunliffe, V. T.
机构
[1] Univ Sheffield, MRC, Ctr Dev Dev & Biomed Genet, Sheffield S10 2TN, S Yorkshire, England
[2] Univ Sheffield, Acad Urol Unit, Sect Oncol, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England
基金
英国医学研究理事会;
关键词
EZH2; prostate cancer; proliferation; invasion;
D O I
10.1002/pros.20550
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. The transcriptional repressor EZH2 is implicated in control of cell proliferation in embryonic, immortalized and transformed cells. EZH2 expression in prostate cancer correlates with progression to hormone-refractory and metastatic disease, but it is unknown whether EZH2 plays a specific role in the acquisition of an advanced prostate cancer phenotype. METHODS. Using siRNA knockdown, we investigated the role of EZH2 in maintenance of prostate cancer cell proliferation and invasiveness. Using LNCaP cells with inducible EZH2 overexpression, we investigated whether EZH2 upregulation promotes an aggressive phenotype. RESULTS. Knockdown of endogenous EZH2 reduced proliferation of androgen-responsive and androgen-independent prostate cancer cells. EZH2 knockdown also inhibited prostate cancer cell invasion. However, overexpression of EZH2 in androgen-responsive cancer cells did not appreciably affect either proliferation or invasiveness. CONCLUSIONS. EZH2 promotes proliferation and invasion of prostate cancer cells, which can account for the correlation between EZH2 expression levels and an adverse prostate cancer prognosis.
引用
收藏
页码:547 / 556
页数:10
相关论文
共 42 条
[1]   Increased expression of EZH2, a polycomb group protein, in bladder carcinoma [J].
Arisan, S ;
Buyuktuncer, ED ;
Palavan-Unsal, N ;
Çaskurlu, T ;
Çakir, OO ;
Ergenekon, E .
UROLOGIA INTERNATIONALIS, 2005, 75 (03) :252-257
[2]  
Berezovska OP, 2006, CELL CYCLE, V5, P1886
[3]   EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J].
Adrian P. Bracken ;
Diego Pasini ;
Maria Capra ;
Elena Prosperini ;
Elena Colli ;
Kristian Helin .
The EMBO Journal, 2003, 22 (20) :5323-5335
[4]   Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis [J].
Breuer, RHJ ;
Snijders, PJF ;
Smit, EF ;
Sutedja, TG ;
Sewalt, RGAB ;
Otte, AP ;
van Kemenade, FJ ;
Postmus, PE ;
Meijer, CJLM ;
Raaphorst, FM .
NEOPLASIA, 2004, 6 (06) :736-743
[5]  
*CANC RES, CANC INC STAT
[6]   Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer [J].
Collett, K ;
Eide, GE ;
Arnes, J ;
Stefansson, IM ;
Eide, J ;
Braaten, A ;
Aas, T ;
Otte, AP ;
Akslen, LA .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1168-1174
[7]   The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype [J].
Croonquist, PA ;
Van Ness, B .
ONCOGENE, 2005, 24 (41) :6269-6280
[8]   Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues [J].
Ding, L ;
Erdmann, C ;
Chinnaiyan, AM ;
Merajver, SD ;
Kleer, CG .
CANCER RESEARCH, 2006, 66 (08) :4095-4099
[9]   Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast [J].
Ding, Lei ;
Kleer, Celina G. .
CANCER RESEARCH, 2006, 66 (19) :9352-9355
[10]   Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome [J].
Foster, CS ;
Falconer, A ;
Dodson, AR ;
Norman, AR ;
Dennis, N ;
Fletcher, A ;
Southgate, C ;
Dowe, A ;
Dearnaley, D ;
Jhavar, S ;
Eeles, R ;
Feber, A ;
Cooper, CS .
ONCOGENE, 2004, 23 (35) :5871-5879